We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva (TEVA) Beats on Q3 Earnings, Lags Sales, Shares Up
Read MoreHide Full Article
Israel-based Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. The company’s branded products include Copaxone (multiple sclerosis), Azilect (Parkinson’s disease), Austedo (chorea associated with Huntington’s disease and tardive dyskinesia) and respiratory products like ProAir and Qvar.
Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva is progressing well on its strategic/restructuring initiatives to revive growth.
Teva’s earnings surpassed expectations in three of the last four quarters, resulting in an average positive surprise of 16.18%.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Teva’s third-quarter earnings came in at 68 cents per share which beat consensus estimate of 55 cents.
Revenues Miss: Teva posted revenues of $4.53 billion, which missed consensus estimates of $4.58 billion. Sales declined 19% (down 18% in constant currency terms) year over year.
Key Statistics: North America segment sales were $2.27 billion, down 26% year over year due to pricing erosion in U.S. generics market, lower sales of Copaxone as well as some other branded drugs and divestiture of some non-core assets in the Women’s Health business. In the United States, revenues declined 27% to $2.1 billion.
Lead branded product, Copaxone, posted sales of $463 million in North America, down 43% year over year due to generic competition for the 20 mg as well as the 40 mg formulation. Sales of generic products declined 25% to $922 million.
The Europe segment recorded revenues of $1.21 billion, down 12% (down 11% in constant currency terms) year over year. In the International Markets segments, sales declined 12% in constant currency terms.
2018 Outlook Up: Teva tightened its 2018 sales guidance while raising the earnings outlook. The revenue outlook was raised from a range of $18.5 - $19.0 billion to $18.6 - $19.0 billion. Meanwhile, the earnings guidance was raised from a band of $2.55-2.80 per share to $2.80-2.95 per share.
Share Price Impact: Shares were up more than 6% in pre-market trading.
Check back later for our full write up on this TEVA earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Teva (TEVA) Beats on Q3 Earnings, Lags Sales, Shares Up
Israel-based Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. The company’s branded products include Copaxone (multiple sclerosis), Azilect (Parkinson’s disease), Austedo (chorea associated with Huntington’s disease and tardive dyskinesia) and respiratory products like ProAir and Qvar.
Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva is progressing well on its strategic/restructuring initiatives to revive growth.
Teva’s earnings surpassed expectations in three of the last four quarters, resulting in an average positive surprise of 16.18%.
Currently, TEVA has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Teva’s third-quarter earnings came in at 68 cents per share which beat consensus estimate of 55 cents.
Revenues Miss: Teva posted revenues of $4.53 billion, which missed consensus estimates of $4.58 billion. Sales declined 19% (down 18% in constant currency terms) year over year.
Key Statistics: North America segment sales were $2.27 billion, down 26% year over year due to pricing erosion in U.S. generics market, lower sales of Copaxone as well as some other branded drugs and divestiture of some non-core assets in the Women’s Health business. In the United States, revenues declined 27% to $2.1 billion.
Lead branded product, Copaxone, posted sales of $463 million in North America, down 43% year over year due to generic competition for the 20 mg as well as the 40 mg formulation. Sales of generic products declined 25% to $922 million.
The Europe segment recorded revenues of $1.21 billion, down 12% (down 11% in constant currency terms) year over year. In the International Markets segments, sales declined 12% in constant currency terms.
2018 Outlook Up: Teva tightened its 2018 sales guidance while raising the earnings outlook. The revenue outlook was raised from a range of $18.5 - $19.0 billion to $18.6 - $19.0 billion. Meanwhile, the earnings guidance was raised from a band of $2.55-2.80 per share to $2.80-2.95 per share.
Share Price Impact: Shares were up more than 6% in pre-market trading.
Check back later for our full write up on this TEVA earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>